Botulinum neurotoxin type A injections reduce spasticity in mild to moderate hereditary spastic paraplegia-report of 19 cases

Movement Disorders

Volumn 23, Issue 2, 2008, Pages 228-233

  Hecht, Martin J ^a,b   Stolze, Henning ^c,d   dem Brinke, Matthias Auf ^b   Giess, Ralf ^b   Treig, Thoams ^e,f   Winterholler, Martin ^g   Wissel, Jörg ^b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Department of Neurology BKH Kaufbeuren ^*  (Germany)

^c UNIVERSITY OF KIEL   (Germany)

^d Diako Hospital   (Germany)

^e UNIVERSITY OF GREIFSWALD   (Germany)

^f Neurological Rehabilitation Centre   (Germany)

^g Rummelsberger Kliniken   (Germany)

Author keywords

Botulinum toxin A; Hereditary spastic paraplegia; HSP; Spasticity; Therapy

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; TIZANIDINE;

ADULT; AGED; ARTICLE; BICYCLE; CLINICAL ARTICLE; DISEASE DURATION; DRUG MEGADOSE; FAMILY HISTORY; FEMALE; FLEXOR MUSCLE; GAIT DISORDER; GENE MUTATION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; MALE; MUSCLE BIOPSY; MUSCLE WEAKNESS; MYOPATHY; NEUROLOGIC EXAMINATION; PAIN; PALLIATIVE THERAPY; PHYSICAL EXAMINATION; PHYSIOTHERAPIST; PHYSIOTHERAPY; PRIORITY JOURNAL; SPASTICITY; SYMPTOMATOLOGY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WALKING AID; WALKING SPEED;

ADOLESCENT; ADULT; AGED; BOTULINUM TOXIN TYPE A; CHILD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; SPASTIC PARAPLEGIA, HEREDITARY;

EID: 39749193869     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21809     Document Type: Article

References (13)

1. Fink J. The hereditary spastic paraplegias. In: Beal M, Lang AEL, Ludolph AC, editors. Neurodegenerative diseases. Cambridge: Cambridge University Press; 2005. p 794-802.
2. Klebe S, Stolze H, Kopper F, et al. Gait analysis of sporadic and hereditary spastic paraplegia. J Neurol 2004;251:571-578.
3. Penn R. Intrathecal baclofen for spasticity of spinal origin: seven years of experience. J Neurosurg 1992;77:236-240.
4. Klebe S, Stolze H, Kopper F, et al. Objective assessment of gait after intrathecal baclofen in hereditary spastic paraplegia. J Neurol 2005;252:991-993.
5. Ward AB, Aguilar M, De Beyl Z, et al. Use of botulinum toxin type A in management of adult spasticity-a European consensus statement. J Rehabil Med 2003;35:98-99.
6. Esquenazi A. Falls and fractures in older post-stroke patients with spasticity: consequences and drug treatment considerations. Clin Geriatr 2004;12:27-35.
7. Chen R, Karp BI, Goldstein SR, Bara-Jiminez W, Yaseen Z, Hallett M. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Mov Disord 1999;14:307-312.
8. Hesse R, Reiter F, Konrad MTJ. Botulinum toxin type A and short-term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: a randomised, double-blind placebocontrolled trial. Clin Rehabil 1998;12:381-388.
9. Frasson E, Priori A, Ruzzante B, Didone G, Bertolasi L. Nerve stimulation boosts botulinum toxin action in spasticity. Mov Disord 2005;20:624-629.
10. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000;68:707-712.
11. Wissel J, Entner T. Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis. Wien Klin Wochenschr 2001;113 (Suppl 4):20 -24.
12. Burbaud P, Wiart L, Dubos J, et al. A randomised, double blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients. J Neurol Neurosurg Psychiatry 1996;61:265-269.
13. Pittock SJ, Moore AP, Hardiman O, et al. A double-blind randomised placebo-controlled evaluation of three doses of botulinum toxin type A (Dysport) in the treatment of spastic equinovarus deformity after stroke. Cerebrovasc Dis 2003;15:289-300.